Shenyang Xingqi Pharmaceutical Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Dec'23

Net Sales

617.97

528.50

498.44

539.61

534.09

345.82

358.85

Other Operating Income

0.00

Total Operating income

617.97

528.50

498.44

539.61

534.09

345.82

358.85

Raw Material Cost

127.99

116.08

119.09

125.51

120.25

92.74

92.61

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

1.30

1.50

1.65

1.80

1.66

0.61

0.62

Selling and Distribution Expenses

233.48

199.82

233.92

220.65

219.97

181.36

160.38

Other Expenses

3.96

4.18

7.65

5.60

3.60

3.45

4.26

Total Expenditure (Excl Depreciation)

402.40

359.21

431.16

403.93

377.88

309.20

296.19

Operating Profit (PBDIT) excl Other Income

215.6

169.3

67.30000000000001

135.7

156.2

36.6

62.699999999999996

Other Income

-5.85

16.15

-8.15

5.01

7.61

3.88

5.81

Operating Profit (PBDIT)

235.14

205.70

85.27

165.80

186.65

68.59

86.62

Interest

1.30

1.50

1.65

1.80

1.66

0.61

0.62

Exceptional Items

0.00

Gross Profit (PBDT)

489.97

412.42

379.36

414.10

413.84

253.07

266.24

Depreciation

26.66

26.46

26.33

23.69

Profit Before Tax

207.17

177.53

57.17

137.53

158.67

41.66

62.30

Tax

18.24

31.64

9.87

16.09

24.10

6.91

4.60

Provisions and contingencies

0.00

Profit After Tax

188.93

145.90

47.30

121.44

134.57

34.75

57.70

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

188.93

145.90

47.30

121.44

134.57

34.75

57.70

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

188.93

145.90

47.30

121.44

134.57

34.75

57.70

Equity Capital

0.00

Face Value

1.0

Reserves

1,758.16

1,743.26

1,593.17

1,627.76

1,504.08

1,736.67

1,689.92

Earnings per share (EPS)

0.77

0.59

0.19

0.5

0.55

0.14

0.24

Diluted Earnings per share

0.77

0.59

0.19

0.5

0.55

0.14

0.24

Operating Profit Margin (Excl OI)

34.68%

30.82%

13.43%

24.89%

28.59%

11.1%

15.92%

Gross Profit Margin

37.84%

38.64%

16.78%

30.39%

34.64%

19.66%

23.96%

PAT Margin

30.57%

27.61%

9.49%

22.51%

25.2%

10.05%

16.08%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Jun 2025 is 15.71% vs 35.66% in Jun 2024

Consolidate Net Profit

YoY Growth in quarter ended Jun 2025 is 40.34% vs 96.78% in Jun 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Jun 2025 is 34.64% vs 91.04% in Jun 2024

Interest

YoY Growth in quarter ended Jun 2025 is -23.53% vs 750.00% in Jun 2024

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Jun 2025 has improved from Jun 2024

Compare Quarterly Results Of Shenyang Xingqi Pharmaceutical Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

617.97

Other Operating Income

0.00

Total Operating income

617.97

Raw Material Cost

127.99

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

1.30

Selling and Distribution Expenses

233.48

Other Expenses

3.96

0.00

3.96

Total Expenditure (Excl Depreciation)

402.40

Operating Profit (PBDIT) excl Other Income

215.57

0.00

215.57

Other Income

-5.85

Operating Profit (PBDIT)

235.14

Interest

1.30

Exceptional Items

0.00

Gross Profit (PBDT)

489.97

Depreciation

26.66

Profit Before Tax

207.17

Tax

18.24

Provisions and contingencies

0.00

Profit After Tax

188.93

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

188.93

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

188.93

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

1,758.16

Earnings per share (EPS)

0.77

Diluted Earnings per share

0.77

Operating Profit Margin (Excl OI)

34.68%

0.00

34.68%

Gross Profit Margin

37.84%

0.00

37.84%

PAT Margin

30.57%

0.00

30.57%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 61.80 Million

in Jun 2025

Figures in Million

QoQ Growth in quarter ended Jun 2025 is 16.93% vs 6.04% in Mar 2025

YoY Growth in quarter ended Jun 2025 is 15.71% vs 35.66% in Jun 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 18.89 Million

in Jun 2025

Figures in Million

QoQ Growth in quarter ended Jun 2025 is 29.47% vs 208.46% in Mar 2025

YoY Growth in quarter ended Jun 2025 is 40.34% vs 96.78% in Jun 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 24.10 Million

in Jun 2025

Figures in Million

QoQ Growth in quarter ended Jun 2025 is 27.11% vs 103.00% in Mar 2025

YoY Growth in quarter ended Jun 2025 is 34.64% vs 91.04% in Jun 2024

Quarterly - Interest

Interest 0.13 Million

in Jun 2025

Figures in Million

QoQ Growth in quarter ended Jun 2025 is -13.33% vs -6.25% in Mar 2025

YoY Growth in quarter ended Jun 2025 is -23.53% vs 750.00% in Jun 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 34.68%

in Jun 2025

Figures in %

QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025

YoY Growth in quarter ended Jun 2025 has improved from Jun 2024